Search
report cover1

Global Myasthenia Gravis Market “(By Type: Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis; By drug: immunosuppressants, corticosteroids, cholinesterase inhibitors & other classes drugs; By distribution channel: Hospital Pharmacies, Retail Pharmacies, Others (e-commerce); By region: North America, Europe, Asia-pacific, south America, middle east & Africa)– Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

A prominent research firm, Cognizance Market Research added a cutting-edge industry report on the “Global Myasthenia Gravis Market.” The report studies the current as well as past growth trends and opportunities for the market to gain valuable insights during the forecast period from 2022 to 2030.

Global Myasthenia Gravis Market Analysis

According to cognizance market research, the Global Myasthenia Gravis Market was valued at US$ 1,589.7 Million in 2022 and is anticipated to reach US$ 2,885.6 Million by the end of 2030 with a CAGR of 7.8% from 2023 to 2030.

myasthenia gravis market

What is the Global Myasthenia Gravis Market?

Myasthenia gravis is an uncommon, chronic, and progressive neuromuscular disorder that affects voluntary muscles in various parts of the body, including the head, limbs, spine, eyes, and throat. This condition disrupts nerve impulse transmission, leading to weakness. The primary cause is the production of antibodies against the acetylcholine receptor (ACHR), which results in the loss of ACHRs. This disturbance impairs the proper transmission of electrical signals from neurons to muscles, leading to skeletal muscle weakness.

While there is no known cure for myasthenia gravis, treatments are available to alleviate its symptoms. People of all ages can be affected by this disorder, but it’s more commonly observed in younger individuals, such as females around the age of 20 and males aged 50 and older. Diagnosis involves various tests like blood tests, electromyograms (EMG), genetic tests, and nerve conduction studies.

According to the National Organization for Rare Diseases (NORD), approximately 14 to 40 individuals per 100,000 are estimated to have myasthenia gravis. The prevalence of this condition has reportedly increased over the past few decades.

Several factors contribute to the growth of this market. These include the rising utilization of immunotherapies, the adoption of potent drugs, the emergence of biologics, and a deeper understanding of rare diseases. Another driving force is the ongoing clinical trials conducted by pharmaceutical companies to develop innovative treatments. With a strong pipeline of potential drugs and a diverse array of options, the market for myasthenia gravis therapies is expected to continue expanding.

Global Myasthenia Gravis Market Outlook

The Global Myasthenia Gravis Market outlook of the report gives a detailed idea about the historical, current & forecast Global Myasthenia Gravis Market trends by analyzing the current therapies which are currently in the market of myasthenia gravis. It also includes market drivers, market restraints & demand for better technology in this market.

Among the therapies, medication has the largest market share, and it is predicted to continue to dominate for the entire anticipated time. This is because medications can drastically suppress the immune system while also treating the associated symptoms. Some examples of drugs include corticosteroids, immunosuppressive drugs like Prograf (tacrolimus), Neoral/Sandimmune, and immunotherapies like Soliris (eculizumab) (cyclosporine). The other primary alternative is surgery, which is the most invasive type of treatment and often involves a thymectomy (thymus removal).

The market for myasthenia gravis treatments is expanding rapidly and will continue to do so during the next years. During the Covid-19 period, the demand for the Covid-19 vaccine has spread around the world because of the daily rise in Covid-19 incidents, increasing demand for research and development as a result. Myasthenia gravis treatment market growth has been hampered since other research and clinical trials have stalled due to an increase in Covid-19 research. It is also hampered due to generic drug competition between the major players in the market and the availability of low-cost alternative treatments.

Myasthenia gravis medication development pipeline studies are multiplying, which is anticipated to drive market expansion. The recent approval of Soliris (eculizumab) by the U.S. FDA and the European Commission is for the treatment of adult patients with generalized myasthenia gravis who are anti-ACHR antibody positive. Soliris is the only complement inhibitor approved for this illness. Immunosuppressants and monoclonal antibodies are being utilized increasingly frequently to lower lifetime corticosteroid exposure and enhance long-term outcomes.

Rising investment in the healthcare sector and in research and development activities to develop advanced technologies for the treatment of myasthenia gravis due to rising demands will drive the market in the forecast period.

Yet, if healthcare prices and per capita income increase globally, there will likely be a greater need for pricey therapies like intravenous immunoglobulin (IVIG) therapy and plasma exchange.

Segment Analysis:

The Global Myasthenia Gravis Market is divided into segments based on the type, the distribution channel, the drugs, and geography.

Based on type there are several different varieties of myasthenia gravis, including ocular myasthenia gravis, congenital myasthenia gravis, generalized myasthenia gravis, and transitory myasthenia gravis. Congenital myasthenia gravis, a hereditary condition, typically manifests as muscle weakness and exhaustion during or shortly after pregnancy, childbirth, or the early years of infancy. It occurs when neurotransmitters, which are substances that aid in information flow between nerve cells and muscles are incorrectly released and absorbed.

Based on end users The Global Myasthenia Gravis Market is segmented, including Hospital Pharmacies, diagnostic centers, and academic and research organizations. The availability of a sizable patient pool and increased demand for sophisticated Myasthenia gravis treatment & advanced technology in various hospital settings helped the hospital segment account for a sizable revenue share in 2022. Also, a large number of patients have visited medical facilities for Myasthenia gravis diagnosis & treatment as a result of the availability of a variety of therapeutic options.

Based on drug type the Global Myasthenia Gravis Market is segmented into Immunosuppressants, corticosteroids, cholinesterase inhibitors, and other drug classes are listed alphabetically. Over the projection period, the pharmaceutical segment is anticipated to contribute the biggest revenue share. This is a result of the increased demand for medications that effectively treat the symptoms while dramatically suppressing the immune system.

Among the therapies, medication has the largest market share, and it is predicted to continue to dominate for the entire anticipated time. Soliris is the only complement inhibitor approved for this illness. Immunosuppressants and monoclonal antibodies are being utilized increasingly frequently to lessen lifetime exposure to corticosteroids and enhance long-term effects.

Geographical Analysis

Geographically, the market for myasthenia gravis has been divided into North America, Asia Pacific, Europe, South America, and the middle east and Africa. Out of all the regions, North America had the greatest market share in 2022, and it is projected that it will maintain its dominance over the market during the forecast period. The prevalence of immunotherapies and monoclonal antibodies, rising healthcare expenses, the existence of reputable institutions for research and development, and a hospitable reimbursement environment all contribute to this.

Asia Pacific is anticipated to grow at the fastest CAGR during the anticipated period due to the growing revenue production from pharmaceuticals like immunosuppressants and monoclonal antibodies in this region. Opportunities are increasing in the MG market, due to a large patient pool, rising healthcare costs in emerging nations, and growing public knowledge of innovative medicines.

Other forces behind the expansion are regional governments’ and manufacturers’ efforts to enhance their financial commitments to the healthcare sector. Myasthenia gravis is expected to have a significant market in North America during the study period, growing at a significant CAGR, and reaching USD xx million in 2022 with a share of around xx%. The region’s aging population and the condition’s increasing prevalence will both have an impact on market growth in the years to come.

Europe has the second-largest market share for treatments for myasthenia gravis. This is due to increased financing and the establishment of several healthcare organizations to identify and treat uncommon diseases like myasthenia gravis.

geographical analysis

The report offers the revenue of the Global Myasthenia Gravis Market for the period 2020-2030, considering 2020 & 2021 as historical years, 2022 as the base year, and 2023 to 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the Global Myasthenia Gravis Market for the forecast period. The Global Myasthenia Gravis Market report provides insights and in-depth analysis into developments impacting enterprises and businesses on a regional and global level. The report covers the Global Myasthenia Gravis Market performance in terms of revenue contribution from several segments and comprises a detailed analysis of key drivers, trends, restraints, and opportunities prompting revenue growth of the Global Myasthenia Gravis Market.

The report has been prepared after wide-ranging secondary and primary research. Secondary research included internet sources, numerical data from government organizations, trade associations, and websites. Analysts have also employed an amalgamation of bottom-up and top-down approaches to study numerous phenomena in the Global Myasthenia Gravis Market. Secondary research involved a detailed analysis of significant players’ product portfolios. Literature reviews, press releases, annual reports, white papers, and relevant documents have been also studied to understand the Global Myasthenia Gravis Market. Primary research involved a great extent of research efforts, wherein experts carried out interviews telephonic as well as questioner-based with industry experts and opinion-makers.

The report includes an executive summary, along with a growth pattern of different segments included in the scope of the study. The Y-o-Y analysis with elaborate market insights has been provided in the report to comprehend the Y-o-Y trends in the Global Myasthenia Gravis Market. Additionally, the report focuses on altering competitive dynamics in the global market. These indices serve as valued tools for present market players as well as for companies interested in participating in the Global Myasthenia Gravis Market. The subsequent section of the myasthenia gravis reports highlights the USPs, which include key industry events (Type launch, research partnership, acquisition, etc.), technology advancements, pipeline analysis, prevalence data, and regulatory scenario.

Global Myasthenia Gravis Market Competitive Landscape

The “Global Myasthenia Gravis Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as,

  • AbbVie, Inc.
  • Alexion Pharmaceutical, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Argenx SE
  • Astellas Pharma, Inc.
  • Avadel Pharmaceuticals PLC
  • Bausch Health Companies Inc.
  • Baxter International, Inc.
  • CSL Behring
  • CuraVac, Inc.
  • Hoffmann-La Roche, Ltd.
  • GlaxoSmithKline plc
  • Grifols SA
  • Immunovant, Inc.
  • Mitsubishi Tanabe Pharma Corp.
  • Novartis AG, RA Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • UCB Pharma
  • Valeant Pharmaceuticals International, Inc.

The report explores the competitive scenario of the Global Myasthenia Gravis Market. Major players operating in the Global Myasthenia Gravis Market have been identified and profiled for unique commercial attributes. Company overview (company description, product portfolio, geographic presence, employee strength, Key management, etc.), financials, SWOT analysis, recent developments, and key strategies are some of the features of companies profiled in the Global Myasthenia Gravis Market report. Customers can use the report’s format to not only make informed judgments about the sector but also to ensure that it continues to expand steadily over time. The intention is to direct clients toward the continuous expansion of their industry.

Segmentation:

Global Myasthenia Gravis Market, by Type

  • Ocular Myasthenia Gravis
  • Congenital Myasthenia Gravis
  • Generalized Myasthenia Gravis
  • Transient Myasthenia Gravis.

Global Myasthenia Gravis Market, by Drug Class

  • Immunosuppressants
  • Corticosteroids
  • Cholinesterase Inhibitors
  • Other Drug Classes

Global Myasthenia Gravis Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others (E-Commerce)

Global Myasthenia Gravis Market, by region

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of the Middle East & Africa
Complete the form below and we'll get back to you shortly
Table of Content

Research Methodology: Aspects

Market research is a crucial tool for organizations aiming to navigate the dynamic landscape of customer preferences, business trends, and competitive landscapes. At Cognizance Market Research, acknowledging the importance of robust research methodologies is vital to delivering actionable insights to our clientele. The significance of such methodologies lies in their capability to offer clarity in complexity, guiding strategic management with realistic evidence rather than speculation. Our clientele seek insights that excel superficial observations, reaching deep into the details of consumer behaviours, market dynamics, and evolving opportunities. These insights serve as the basis upon which businesses craft tailored approaches, optimize product offerings, and gain a competitive edge in an ever-growing marketplace.

The frequency of information updates is a cornerstone of our commitment to providing timely, relevant, and accurate insights. Cognizance Market Research adheres to a rigorous schedule of data collection, analysis, and distribution to ensure that our reports reflect the most current market realities. This proactive approach enables our clients to stay ahead of the curve, capitalize on emerging trends, and mitigate risks associated with outdated information.

Our research process is characterized by meticulous attention to detail and methodological rigor. It begins with a comprehensive understanding of client objectives, industry dynamics, and research scope. Leveraging a combination of primary and secondary research methodologies, we gather data from diverse sources including surveys, interviews, industry reports, and proprietary databases. Rigorous data analysis techniques are then employed to derive meaningful insights, identify patterns, and uncover actionable recommendations. Throughout the process, we remain vigilant in upholding the highest standards of data integrity, ensuring that our findings are robust, reliable, and actionable.

Key phases involved in in our research process are mentioned below:

slide1

Understanding Clients’ Objectives:

Extensive Discussions and Consultations:

  • We initiate in-depth discussions and consultations with our clients to gain a comprehensive understanding of their objectives. This involves actively listening to their needs, concerns, and aspirations regarding the research project.
  • Through these interactions, we aim to uncover the underlying motivations driving their research requirements and the specific outcomes they hope to achieve.

Industry and Market Segment Analysis:

  • We invest time and effort in comprehensively understanding our clients’ industry and market segment. This involves conducting thorough research into market trends, competitive dynamics, regulatory frameworks, and emerging opportunities or threats.
  • By acquiring a deep understanding of the broader industry landscape, we can provide context-rich insights that resonate with our clients’ strategic objectives.

Target Audience Understanding:

  • We analyze our clients’ target audience demographics, behaviors, preferences, and needs to align our research efforts with their consumer-centric objectives. This entails segmenting the audience based on various criteria such as age, gender, income level, geographic location, and psychographic factors.
  • By understanding the nuances of the target audience, we can tailor our research methodologies to gather relevant data that illuminates consumer perceptions, attitudes, and purchase intent.

slide2

Identifying Challenges and Opportunities:

  • We proactively identify the challenges and opportunities facing our clients within their respective industries. This involves conducting SWOT (Strengths, Weaknesses, Opportunities, Threats) analyses and competitive benchmarking exercises.
  • By identifying potential obstacles and growth drivers, we can provide strategic recommendations that help our clients navigate complexities and capitalize on emerging opportunities effectively.

Grasping Specific Goals:

  • We delve into the intricacies of our clients’ objectives to gain clarity on the specific goals they aim to accomplish through the research. This entails understanding their desired outcomes, such as market expansion, product development, or competitive analysis.
  • By gaining a nuanced understanding of our clients’ goals, we can tailor our research approach to address their unique challenges and opportunities effectively.

Data Collection:

slide3

Primary Research Process:

  • Surveys: We design and administer surveys tailored to capture specific information relevant to our clients’ objectives. This may involve employing various survey methodologies, such as online, telephone, or face-to-face interviews, to reach target audiences effectively.
  • Interviews: We conduct structured or semi-structured interviews with key stakeholders, industry experts, or target consumers to gather in-depth insights and perspectives on relevant topics. These interviews allow us to probe deeper into specific issues and uncover valuable qualitative data.
  • Focus Groups: We organize focus group discussions with carefully selected participants to facilitate interactive discussions and gather collective opinions, attitudes, and preferences. This qualitative research method provides rich contextual insights into consumer behaviors and perceptions.
  • Observations: We conduct observational research by directly observing consumer behaviors, interactions, and experiences in real-world settings. This method enables us to gather objective data on consumer actions and reactions without relying on self-reported information.

Secondary Research Process:

  • Literature Review: We conduct comprehensive literature reviews to identify existing studies, academic articles, and industry reports relevant to the research topic. This helps us gain insights into previous research findings, theoretical frameworks, and best practices.
  • Industry Reports: We analyze industry reports published by reputable trade associations (whitepapers, research studies, etc.), and government agencies (U.S. Census Bureau, Bureau of Labor Statistics, and Securities and Exchange Commission etc.) to obtain macro-level insights into market trends, competitive landscapes, and industry dynamics.
  • Government Publications: We review government publications, such as economic reports, regulatory documents, and statistical databases, to gather relevant data on demographics, market size, consumer spending patterns, and regulatory frameworks.
  • Online Databases: We leverage online databases, such as industry portals, and academic repositories (PubMed Central (PMC), ScienceDirect, SSRN (Social Science Research Network), Directory of Open Access Journals (DOAJ), NCBI, etc.), to access a wide range of secondary data sources, including market statistics, financial data, and industry analyses.

slide4

slide5

 

 

Data Analysis:

The data analysis phase serves as a critical juncture where raw data is transformed into actionable insights that inform strategic decision-making. Through the utilization of analytical methods such as statistical analysis and qualitative techniques like thematic coding, we uncover patterns, correlations, and trends within the data. By ensuring the integrity and validity of our findings, we strive to provide clients with accurate and reliable insights that accurately reflect the realities of the market landscape.

slide6

 

Transformation of Raw Data:

  • Upon collecting the necessary data, we transition into the data analysis phase, where raw data is processed and transformed into actionable insights. This involves organizing, cleaning, and structuring the data to prepare it for analysis.

Utilization of Analytical Methods:

  • Depending on the research objectives, we employ a diverse range of analytical methods to extract meaningful insights from the data. These methods include statistical analysis, trend analysis, regression analysis, and qualitative coding.

Statistical Analysis:

  • Statistical tools are instrumental in uncovering patterns, correlations, and trends within the data. By applying statistical techniques such as descriptive statistics, hypothesis testing, and multivariate analysis, we can discern relationships and derive valuable insights.

Qualitative Analysis Techniques:

  • In addition to quantitative analysis, we leverage qualitative analysis techniques to gain deeper insights from qualitative data sources such as interviews or open-ended survey responses. One such technique is thematic coding, which involves systematically categorizing and interpreting themes or patterns within qualitative data.

Integrity and Validity Maintenance:

  • Throughout the analysis process, we maintain a steadfast commitment to upholding the integrity and validity of our findings. This entails rigorous adherence to established methodologies, transparency in data handling, and thorough validation of analytical outcomes.

Data Validation:

The final phase of our research methodology is data validation, which is essential for ensuring the reliability and credibility of our findings. Validation involves scrutinizing the collected data to identify any inconsistencies, errors, or biases that may have crept in during the research process. We employ various validation techniques, including cross-referencing data from multiple sources, conducting validity checks on survey instruments, and seeking feedback from independent experts or peer reviewers. Additionally, we leverage internal quality assurance protocols to verify the accuracy and integrity of our analysis. By subjecting our findings to rigorous validation procedures, we instill confidence in our clients that the insights they receive are robust, reliable, and trustworthy.

slide7

Importance of Data Validation:

  • Data validation is the final phase of the research methodology, crucial for ensuring the reliability and credibility of the findings. It involves a systematic process of reviewing and verifying the collected data to detect any inconsistencies, errors, or biases.

Scrutiny of Collected Data:

  • The validation process begins with a thorough scrutiny of the collected data to identify any discrepancies or anomalies. This entails comparing data points, checking for outliers, and verifying the accuracy of data entries against the original sources.

Validation Techniques:

  • Various validation techniques are employed to ensure the accuracy and integrity of the data. These include cross-referencing data from multiple sources to corroborate findings, conducting validity checks on survey instruments to assess the reliability of responses, and seeking feedback from independent experts or peer reviewers to validate the interpretation of results.

Internal Quality Assurance Protocols:

  • In addition to external validation measures, internal quality assurance protocols are implemented to further validate the accuracy of the analysis. This may involve conducting internal audits, peer reviews, or data validation checks to ensure that the research process adheres to established standards and guidelines.

Report Scope:

Attribute

Description

Market Size

US$ 2,885.6 Million (2030)

Compound Annual Growth Rate (CAGR)

7.80%

Base Year

2022

Forecast Period

2023-2030

Forecast Units

Value (US$ Million)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Geographies Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Countries Covered

U.S., Canada, Germany, U.K., France, Spain, Italy, Rest of Europe, Japan, China, India, Australia & New Zealand, South Korea, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, GCC, South Africa, Rest of Middle East & Africa

Key Companies Profiled

AbbVie, Inc., Alexion Pharmaceutical, Inc., Amneal Pharmaceuticals, Inc., Argenx SE, Astellas Pharma, Inc., Avadel Pharmaceuticals PLC, Bausch Health Companies Inc.

Key Questions Answered in Myasthenia Gravis Market Report

AbbVie, Inc., Alexion Pharmaceutical, Inc., Amneal Pharmaceuticals, Inc., Argenx SE, Astellas Pharma, Inc., Avadel Pharmaceuticals PLC, Bausch Health Companies Inc., etc.

Trend: Increased public awareness and disease diagnosis. Drivers: novel therapies are growing. Opportunities: medical condition payment regulations advance. Challenges: efforts to create and win approval for new drugs to treat the condition as a result.

Companies are deploying various strategies, strategic agreements, acquisitions & mergers, new testing, & investing to develop effective treatments.

AbbVie, Inc., Alexion Pharmaceutical, Inc., Amneal Pharmaceuticals, Inc., Argenx SE, Astellas Pharma, Inc., Avadel Pharmaceuticals PLC, Bausch Health Companies Inc., etc.

It is estimated to reach US$ 2,885.6 Million by the end of 2030

Goodbye 2024: Special Year-End Sale!

US$ 4600.00

Single User - $2300.00

It allows one person, the buyer, to have the sole rights and access to the purchased report. Further distribution of the product is strictly prohibited.

US$ 6500.00

Team User - $3250.00

It allows the purchased product to be shared among 1-7 employees of your organization within the same geographical location.

US$ 8500.00

Corporate User - $4250.00

It allows the purchased product to be shared among all employees of your organization irrespective of their geographical location.

Need a Custom Report?

We can customize every report – free of charge – including purchasing stand-alone sections or country-level reports

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Business Development

small c popup.png
Complete the form below and we'll get back to you shortly
Customization
small c popup.png
Complete the form below and we'll get back to you shortly
Discount
small c popup.png
Complete the form below and we'll get back to you shortly
Ask an Expert